An extended mid-stage trial of Human Genome Science's lymphostat for lupus has produced new positive data on the drug. The results come a year after HGS concluded that 24-week data on 449 patients did not show that lymphostat-B reduced symptoms in the disease. In June, though, HGS announced that 52 week data did demonstrate efficacy and this new data is from 76 weeks of results on 321 patients. HGS said the response rate to the drug jumped from 46 percent to 56 percent. A late-stage trial is expected to get underway by the end of the year.
- see the company's press release on the data
- read the AP report
Related Articles:
HGS signs $425M deal for BioMed Realty campus. Report
Lupus drug fails Phase 2, HGS sees positive effects. Report
Feds ink HGS contract. Report